Last reviewed · How we verify
Insulin Lispro 6 Day (6D)
Insulin Lispro 6 Day is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues.
Insulin Lispro 6 Day is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin Lispro 6 Day (6D) |
|---|---|
| Also known as | Insulin Lispro Formulation, Humalog, LY275585 |
| Sponsor | Eli Lilly and Company |
| Drug class | Rapid-acting insulin analog |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Insulin Lispro is a recombinant human insulin analog with a rapid onset of action, designed to mimic the body's natural insulin response to meals. The 6 Day formulation refers to an extended duration of action variant, allowing for potentially longer intervals between injections while maintaining glycemic control. It works by binding to insulin receptors on muscle and adipose tissue, promoting glucose uptake and storage while suppressing hepatic glucose production.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |